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Abstract
Objective:  To  evaluate  musculoskeletal  involvement  and  autoantibodies  in  pediatric  leprosy
patients.
Methods: 50  leprosy  patients  and  47  healthy  children  and  adolescents  were  assessed  according
to musculoskeletal  manifestations  (arthralgia,  arthritis,  and  myalgia),  musculoskeletal  pain
syndromes  (juvenile  ﬁbromyalgia,  benign  joint  hypermobility  syndrome,  myofascial  syndrome,
and  tendinitis),  and  a  panel  of  autoantibodies  and  cryoglobulins.  Health  assessment  scores  and
treatment  were  performed  in  leprosy  patients.
Results:  At  least  one  musculoskeletal  manifestation  was  observed  in  14%  of  leprosy  patients  and
in  none  of  the  controls.  Five  leprosy  patients  had  asymmetric  polyarthritis  of  small  hands  joints.
Nerve  function  impairment  was  observed  in  22%  of  leprosy  patients,  type  1  leprosy  reaction  in
18%,  and  silent  neuropathy  in  16%.  None  of  the  patients  and  controls  presented  musculoskele-
tal pain  syndromes,  and  the  frequencies  of  all  antibodies  and  cyoglobulins  were  similar  in  both
groups  (p  >  0.05).  Further  analysis  of  leprosy  patients  demonstrated  that  the  frequencies  of
nerve  function  impairment,  type  1  leprosy  reaction,  and  silent  neuropathy  were  signiﬁcantly
observed  in  patients  with  versus  without  musculoskeletal  manifestations  (p  =  0.0036,  p  =  0.0001,
and  p  =  0.309,  respectively),  as  well  as  multibacillary  subtypes  in  leprosy  (86%  vs.  42%,  p  =
0.045).  The  median  of  physicians’  visual  analog  scale  (VAS),  patients’  VAS,  pain  VAS,  and  Child-
hood  Health  Assessment  Questionnaire  (CHAQ)  were  signiﬁcantly  higher  in  leprosy  patients  with
musculoskeletal  manifestations  (p  =  0.0001,  p  =  0.002,  p  =  0002,  and  p  =  0.001,  respectively).
 Please cite this article as: Neder L, Rondon DA, Cury SS, da Silva CA. Musculoskeletal manifestations and autoantibodies in children and
adolescents with leprosy. J Pediatr (Rio J). 2014;90:457--63.
∗ Corresponding author.
E-mail: clovisaasilva@gmail.com (C.A. Silva).
http://dx.doi.org/10.1016/j.jped.2014.01.007
0021-7557/© 2014 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
458  Neder  L  et  al.
Conclusions:  This  was  the  ﬁrst  study  to  identify  musculoskeletal  manifestations  associated  with
nerve  dysfunction  in  pediatric  leprosy  patients.  Hansen’s  disease  should  be  included  in  the
differential  diagnosis  of  asymmetric  arthritis,  especially  in  endemic  regions.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Manifestac¸ões  musculoesqueléticas  e  autoanticorpos  em  crianc¸as  e  adolescentes  com
hanseníase
Resumo
Objetivo:  Avaliar  o  envolvimento  musculoesquelético  e  os  autoanticorpos  em  pacientes
pediátricos com  hanseníase.
Métodos: Foram  avaliados  50  pacientes  com  hanseníase  e  47  crianc¸as  e  adolescentes  saudáveis
de acordo  com  manifestac¸ões  musculoesqueléticas  (artralgia,  artrite  e  mialgia),  síndromes
dolorosas  musculoesqueléticas  (ﬁbromialgia  juvenil,  síndrome  de  hipermobilidade  articular
benigna,  síndrome  miofascial  e  tendinite)  e  painel  de  autoanticorpos  e  crioglobulinas.  Escores
de  avaliac¸ão  de  saúde  e  tratamento  foram  realizados  nos  pacientes  com  hanseníase.
Resultados: Pelo  menos  uma  manifestac¸ão  musculoesquelética  foi  observada  em  14%  dos
pacientes com  hanseníase  e  em  nenhum  controle.  Dentre  os  pacientes  com  hanseníase,  cinco
tinham  poliartrite  assimétrica  das  pequenas  articulac¸ões  das  mãos.  Comprometimento  da
func¸ão  do  nervo  foi  observado  em  22%  dos  pacientes  com  hanseníase,  reac¸ão  tipo  I  hansênica  em
18%  e  neuropatia  silenciosa  em  16%.  Nenhum  dos  pacientes  e  controles  apresentou  síndromes  de
dor  musculoesquelética  e  as  frequências  dos  anticorpos  e  crioglobulinas  foram  semelhantes  nos
dois  grupos  (p  >  0,05).  Comprometimentos  da  func¸ão  nervosa,  reac¸ão  hansênica  tipo  I e  neuropa-
tia  silenciosa  foram  observados  em  pacientes  com  vs  sem  manifestac¸ões  musculoesqueléticas
(p =  0,0036,  p  =  0,0001  e  p  =  0,309,  respectivamente),  bem  como  subtipos  de  hanseníase  multi-
bacilar  (86%  vs  42%,  p  =  0,045).  A  escala  visual  analógica  (EVA)  do  médico,  dos  pacientes,  e  da  dor
e  o  Questionário  de  Avaliac¸ão  de  Saúde  Infantil  foram  maiores  em  pacientes  com  manifestac¸ões
musculoesqueléticas  (p  =  0,0001,  p  =  0,002,  p  =  0002  e  p  =  0,001,  respectivamente).
Conclusão: Este  foi  o  primeiro  estudo  a  identiﬁcar  manifestac¸ões  musculoesqueléticas  asso-
ciadas com  disfunc¸ão  de  nervos  periféricos  em  pacientes  pediátricos.  A  hanseníase  deve  ser
incluída  no  diagnóstico  diferencial  de  artrite  assimétrica,  principalmente  em  regiões  endêmi-
cas.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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The control  group  included  47  healthy  children  and  ado-
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eprosy  is  a  chronic  infectious  disease  caused  by  Mycobac-
erium leprae.  It  is  considered  a  major  public  health  issue  in
eveloping countries  and  has  been  rarely  described  in  pedi-
tric population,  which  comprises  6%  to  14%  of  all  leprosy
ases,1,2 with  an  average  of  7%  in  Brazil.3
The  important  clinical  signs  of  leprosy  are  hypopig-
ented or  reddish  localized  skin  lesions  with  loss  of
ensation and  peripheral  nerves  involvement.4,5 Muscu-
oskeletal manifestations  were  described  in  adult  leprosy
atients, especially  acute  and  chronic  arthritis6--12 and
rthralgia,8 and  these  involvements  were  rarely  described
n the  pediatric  leprosy  population.13,14
Autoantibodies  were  also  studied  in  adult  leprosy
atients, especially  antinuclear  antibody  (ANA)9 and
ntiphospholipid.15 Moreover,  there  is  no  study  that  has
imultaneously assessed  musculoskeletal  involvement  and
utoantibodies in  pediatric  leprosy  patients.Therefore,  this  was  a  cross-sectional  study  that
nvestigated the  musculoskeletal  involvement  and  autoan-
ibodies in  pediatric  leprosy  patients  and  healthy  controls.
l
C
Hn  addition,  the  possible  associations  of  musculoskele-
al manifestations  in  leprosy  children  and  adolescents
ith demographic  data,  leprosy  manifestations,  health
ssessment scores,  autoantibodies,  and  treatment  were
valuated.
atients and methods
rom  January  of  2010  to  October  of  2012,  56  leprosy
atients were  followed  up  at  the  Dermatology  Service  of
he Hospital  Universitário  Julio  Muller,  from  the  Universi-
ade Federal  do  Mato  Grosso,  Cuiabá,  Brazil.  Fifty  leprosy
atients agreed  to  participate  in  this  study.  All  patients  were
iagnosed  in  accordance  with  the  National  Leprosy  Program
uidelines5 and  the  Ridley-Jopling  classiﬁcation  criteria,16
s  borderline-borderline  (BB),  borderline-lepromatous  (BL),
epromatous-lepromatous (LL),  borderline-tuberculoid  (BT),
uberculoid-tuberculoid (TT),  or  indeterminate  leprosy  (IL).escent of  the  Escola  Estadual  de  1◦ e  2◦ graus  Bela  Vista,
uiabá, Mato  Grosso,  Brazil.  The  ethical  committees  of  the
ospital Universitário  Julio  Muller  and  of  the  Hospital  das
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Clínicas  da  Universidade  de  São  Paulo  approved  this  study,
and an  informed  consent  was  obtained  from  all  participants
and legal  guardians.
Demographic data and socio-economic classes
Demographic  data  included  current  age  and  gender.  Brazil-
ian socioeconomic  classes  were  classiﬁed  in  accordance  with
the Associac¸ão  Brasileira  dos  Institutos  de  Pesquisa  de  Mer-
cados criteria.17
Musculoskeletal manifestations
Musculoskeletal  manifestations  were  deﬁned  according  to
arthralgia (diffuse  joint  pain  or  tenderness  without  evidence
of inﬂammation),  arthritis  (swelling  within  a  joint,  or  lim-
itation in  the  range  of  joint  movement  with  joint  pain  or
tenderness),18 and  myalgia  (muscle  pain  or  tenderness  in  one
or more  limbs  without  evidence  of  inﬂammation).  Arthritis
were classiﬁed  according  to  the  number  of  joints  (oligoar-
ticular lower  than  four  arthritides  and  polyarticular  [equal
to or  greater  than  ﬁve  arthritides])  and  the  duration  (acute
[lower than  six  weeks]  and  chronic  [equal  to  or  greater  than
six weeks]).18
Musculoskeletal  pain  syndromes
The  following  musculoskeletal  pain  syndromes  were
diagnosed during  musculoskeletal  examination:  juvenile
ﬁbromyalgia,19 myofascial  syndrome,  and  tendinitis.20--22
Juvenile  ﬁbromyalgia  was  diagnosed  in  accordance  with
Yunus and  Masi  criteria.19 Myofascial  syndrome  was  diag-
nosed according  to  active  trigger  points,  which  is  deﬁned  as
painful points  in  taut  bands  of  muscle  ﬁbers.  If  pressured,
these points  induce  reported  pain  that  is  reproducible  and
that affects  speciﬁc  places  for  each  muscle.20--22
Other  ﬁndings  in  musculoskeletal  physical
examination
Joint  hypermobility  (JH)  was  diagnosed  according  to  the
criteria proposed  by  Beighton.  Benign  joint  hypermobility
syndrome was  deﬁned  as  JH  combined  with  musculoskeletal
pain and  ﬁve  of  nine  criteria.23
Clinical  assessment  of  leprosy
Clinical  assessment  of  leprosy  was  performed  in  accordance
with the  Brazilian  Leprosy  Program  guidelines.5 Nerve  func-
tion impairment  is  a  clinically  detectable  loss  of  motor,
sensory, or  autonomic  peripheral  nerve  function.  Type  1
(reversal) leprosy  reaction  is  deﬁned  as  nerve  inﬂammation
with loss  of  sensory  and  motor  functions  and/or  redness  and
swelling in  pre-existing  skin  lesion  and  in  new  lesions.  Silent
neuropathy is  deﬁned  as  the  impairment  of  nerve  function
without any  nerve  pain  or  tenderness.  Type  2  (erythema
nodosum leprosum)  leprosy  reaction  is  deﬁned  as  a  sud-
den appearance  of  superﬁcial  or  deep  crops  on  new  tender
subcutaneous nodules.5
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ealth  assessment  scores  and  treatment  in  leprosy
atients
ll  leprosy  patients  were  evaluated  regarding  physician’s
lobal assessment,  patient’s  global  assessment,  and  pain
sing the  10  cm  Visual  Analog  Scale  (VAS)24 and  the  Childhood
ealth Assessment  Questionnaire  (CHAQ).25
Data  concerning  leprosy  treatment  included:  prednisone
herapy, mutibacillary  therapy  (rifampicin,  dapsone  and
lofazimine), and  paucibacillary  therapy  (rifampicine  and
apsone).5
utoantibodies  and  cryoglobulins
he  laboratory  exams  were  performed  by  a  technician  who
as blinded  to  the  results  of  leprosy  and  musculoskeletal
anifestations.  The  following  serum  autoantibodies  were
easured at  study  admission:  ANA  by  indirect  immunoﬂuo-
escence on  human  cell  epithelioma  (HEp-2)  cells  (GMK
 United  States)  and  staining  reactivity  at  ≥  1:80  serum
ilution deﬁned  as  positive;  anti-double-stranded  DNA  (anti-
s DNA)  by  in-house  indirect  immunoﬂuorescence  using
rithidia luciliae  as  substrate  (GMK  --  United  States)  with
 cut-off  value  of  1:10;  anti-Ro  and  anti-La  by  ﬂuorome-
ry (Phadia  -  Sweden)  with  a  cut-off  <  10.1;  anticardiolipin
aCL) isotypes  IgG  and  IgM  by  enzyme-linked  immunosorbent
ssay (ELISA;  Phadia  -  Sweden),  with  a  cut-off  value  of  20
PL and/or  MPL.  Lupus  anticoagulant  (LAC)  was  assessed  by
he dilute  Russell’s  viper  venom  time  with  a  cut-off  value  <
.15 and  conﬁrmatory  testing  with  a  cut-off  value  <  1.21
Siemens -  Germany).  Cryoglobulin  was  performed  by  in-
ouse gel  immunoelectrophoresis.  HLA  B27  and  rheumatoid
actor (RF)  detections  were  performed  by  in-house  real-time
olymerase chain  reaction  assay  (Arup  Laboratories  -  USA)
nd by  immunoturbidimetric  assays  (Wiener  - Argentina;
ut-off <  20  UI/mL)  in  patients  and  controls  with  arthralgia
nd/or arthritis.
tatistical  analysis
esults  were  presented  as  mean  ±  standard  deviation  or
edian (range)  for  continuous  variables,  and  as  number  (%)
or categorical  variables.  Data  were  compared  by  Student’s
-test or  Mann-Whitney’s  test  for  continuous  variables.  For
ategorical variables,  the  differences  were  assessed  by
isher’s exact  test.  In  all  statistical  tests,  the  level  of  signif-
cance was  set  at  5%  (p  <  0.05).
esults
eprosy  patients  and  healthy  controls
usculoskeletal  and  leprosy  manifestations,  and
usculoskeletal  pain  syndromes
t least  one  musculoskeletal  manifestation  (arthralgia,
rthritis, and/or  myalgia)  was  observed  in  14%  of  leprosy
atients, and  none  was  observed  in  healthy  controls.  Five
eprosy patients  had  asymmetric  polyarthritis  of  small  joints
f the  hands  (metacarpophalangeal  and  proximal  interpha-
angeal joints),  with  median  duration  of  12  months  (ranging
rom 15  days  to  36  months).  Four  patients  with  borderline
eprosy had  chronic  polyarthritis  and  morning  stiffness.
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Table  1  Demographic  data,  clinical  musculoskeletal  manifestations,  and  musculoskeletal  pain  syndromes  in  leprosy  patients
and  healthy  controls.
Variables  Leprosy  patients  (n  =  50)  Controls  (n  =  47)  p-value
Demographic  data
Current age,  median  (range)  12  (3-18)  14  (3-18)  0.385
Female  gender,  n  (%)  25  (50)  25  (53.1)  0.840
Brazilian  socio-economic  classes
Middle/lower  middle  class,  n  (%) 46  (92) 44 (93)  1.000
Clinical  musculoskeletal  manifestations
Musculoskeletal,  n  (%) 7  (14) 0 0.0012a
Arthralgia,  n  (%) 1  (2) 0 1.000
Myalgia,  n  (%)  3  (6)  0  0.243
Musculoskeletal  pain  syndromes
Juvenile ﬁbromyalgia,  n  (%)  0  0  1.000
Benign  joint  hypermobility  syndrome,  n  (%) 0  0  1.000
Myofascial  syndrome,  n  (%) 0  0  1.000
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a Signiﬁcant p-values.
The  most  frequent  leprosy  manifestations  were  hypopig-
ented or  reddish  localized  skin  lesions  with  loss  of
ensation, particularly  of  touch  and  temperature,  observed
n 94%  of  all  leprosy  patients.  Nerve  function  impairment
as observed  in  22%  of  the  leprosy  patients;  type  1  leprosy
eaction, in  18%;  and  silent  neuropathy,  in  16%.  No  lep-
osy patient  had  cutaneous  vasculitis  and  type  2  (erythema
odosum leprosum)  leprosy  reaction.
None  of  the  patients  and  controls  had  juvenile  fybro-
ialgia, benign  joint  hypermobility  syndrome,  myofascial
yndrome, and  tendinitis  in  the  hands  (Table  1).
utoantibodies  and  cryoglobulins
he frequencies  of  all  antibodies  (ANA,  anti-ds  DNA,  anti-Ro,
nti-La, aCL-IgM,  aCl-IgG,  and  LAC)  and  cyoglobulins  were
imilar in  leprosy  patients  and  controls  (Table  2).  HLA  B27
est were  negative  in  all  patients  with  arthralgia  and/or
rthritis. RF  was  positive  in  two  out  of  ﬁve  patients  with
rthralgia and/or  arthritis.eprosy patients  with  and  without  musculoskeletal
anifestations
he frequencies  of  nerve  function  impairment,  type  1
eprosy reaction,  and  silent  neuropathy  were  signiﬁcantly
D
T
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Table  2  Autoantibodies  and  cryoglobulins  in  leprosy  patients  and
Variables  Leprosy  patients  (n  =  50)  
Autoantibodies
ANA,  n  (%)  1  (2)  
Anti-ds  DNA,  n  (%)  0  
Anti-Ro,  n  (%)  0  
Anti-La,  n  (%)  0  
aCL-IgM,  n  (%)  8  (16)  
aCL-IgG,  n  (%)  1  (2)  
LAC,  n  (%)  1  (2)  
Cryoglobulins,  n  (%) 0 
ANA, antinuclear antibody; anti-ds DNA, anti-double-stranded DNA ant
anticardiolipin antibody; IgM, immunoglobulin M; IgG, immunoglobulin0  1.000
bserved  in  leprosy  patients  with  musculoskeletal  manifes-
ations versus  those  without  (71%  vs.  14%,  p  = 0.0036;  71%  vs.
%, p  =  0.0001;  29%  vs.  14%,  p  =  0.309;  respectively),  as  well
s multibacillary  subtypes  in  leprosy  patients  with  muscu-
oskeletal manifestations  (86%  vs.  42%,  p  =  0.045)  (Table  3).
The  median  of  physicians’  VAS,  patients’  VAS,  pain  VAS,
nd CHAQ  were  signiﬁcantly  higher  in  leprosy  patients  with
usculoskeletal manifestations  versus  those  without  these
lterations (p  =  0.0001,  p  =  0.002,  p  =  002,  and  p  =  0.001,
espectively). Leprosy  patients  with  musculoskeletal  man-
festations were  signiﬁcantly  treated  with  prednisone  and
ultibacillary therapies  compared  with  patients  without
hese manifestations  (71%  vs.  0%,  p  =  0.0001;  86%  vs.  42%,  p
 0.045)  (Table  3).
The frequencies  of  all  antibodies  (ANA,  anti-ds  DNA,  anti-
o, anti-La,  aCL-IgM,  aCl-IgG,  and  LAC)  and  cryoglobulins
ere similar  in  leprosy  patients  with  and  without  muscu-
oskeletal manifestations  (Table  4).iscussion
o  the  best  of  the  authors’  knowledge,  this  was  the  ﬁrst
tudy in  a  pediatric  leprosy  population  that  clearly  observed
 healthy  controls.
Controls  (n  =  47)  p-value
0  1.000
0  1.000
0  1.000
0  1.000
6  (13)  0.775
0  1.000
1  (2)  1.000
0  1.000
ibody; anti-Ro, anti-Ro antibody; anti-La, anti-La antibody; aCL,
 G; LAC, lupus anticoagulant.
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Table  3  Demographic  data,  leprosy  clinical  manifestations,  health  assessment  scores,  and  treatment  in  leprosy  patients  with
and without  musculoskeletal  manifestations.
Variables  With  musculoskeletal
manifestations  (n  =  7)
Without  musculoskeletal
manifestations  (n  =  43)
p-value
Demographic  data
Disease onset,  median  (range) 12  (3-16)  10  (2-18)  0.286
Current  age,  median  (range) 13  (6-18) 12  (3-18)  0.280
Female  gender,  n  (%) 4  (57) 21 (49) 1.000
Brazilian  socio-economic  classes
Middle/lower  middle  class,  n  (%) 7 (100) 35 (81) 0.579
Leprosy
Nerve  function  impairment,  n  (%)  5  (71)  6  (14)  0.0036a
Type  I  (reversal)  lepra  reaction,  n  (%)  5  (71)  0  0.0001a
Silent  neuropathy,  n  (%)  2  (29)  6  (14)  0.309
Erythema  nodosum  leprosum,  n  (%) 0 0  1.000
Cutaneous  vasculitis,  n  (%) 0  0  1.000
Multibacillary  (BB,  BL,  or  BT),  n  (%) 6 (86) 18 (42) 0.045a
Paucibacillary  (TT  or  IL),  n  (%) 1 (14) 25 (58) 0.045a
Health  assessment  scores
Physician VAS  (0-10),  median  (range)  8  (0-10)  0  (0-10)  0.0001a
Patient  VAS  (0-10),  median  (range)  0  (0-10)  0  (0-6)  0.002a
Pain  VAS  (0-10),  median  (range)  0  (0-9)  0  (0-8)  0.002a
CHAQ  (0-3),  median  (range)  0  (0-1)  0  (0)  0.001a
Treatment
Prednisone,  n  (%)  5  (71)  0  0.0001a
Multibacillary  therapy,  n  (%)  6  (86)  18  (42)  0.045a
Paucibacillary  therapy,  n  (%)  1  (14)  25  (58)  0.045a
BB, borderline-borderline; BL, borderline-lepromatous; BT, borderline-tuberculoid; TT, tuberculoid-tuberculoid; IL, indeterminate lep-
t Que
t
s
m
Arosy; VAS, visual analog scale; CHAQ, Childhood Health Assessmen
a Signiﬁcant p-values.
musculoskeletal  manifestations,  especially  asymmetric  pol-
yarthritis, associated  with  severe  disease  and  nerve  function
impairment, without  autoantibodies  production.
The  great  advantage  of  the  present  study  design  was  the
systematic evaluation  of  leprosy  and  musculoskeletal  mani-
festations, pain  syndromes,  and  a  panel  of  autoantibodies,
including standardized  deﬁnitions18--23 and  excluding  peri-
articular pain,20--22 in  a  leprosy  population  of  one  state  in
Midwestern Brazil.  Additionally,  a  healthy  control  group  with
m
a
p
a
Table  4  Autoantibodies  and  cryoglobulins  in  leprosy  patients  wit
Variables  With  musculoskeletal
manifestations  (n  =  7)
Autoantibodies
ANA,  n  (%)  0  
Anti-ds  DNA,  n  (%)  0  
Anti-Ro,  n  (%)  0  
Anti-La,  n  (%)  0  
aCL-IgM,  n  (%) 3 (43)  
aCL-IgG,  n  (%)  0  
LAC,  n  (%) 1  (14)  
Cryoglobulins,  n  (%) 0 
ANA, antinuclear antibody; anti-ds DNA, anti-double-stranded DNA ant
anticardiolipin antibody; IgM, immunoglobulin M; IgG, immunoglobulinstionnaire.
he  same  age,  gender,  and  socio-economic  class,  using  the
ame protocol,  was  included.
Importantly,  musculoskeletal  involvement  is  the  third
ost frequent  manifestation  in  adult  leprosy  patients.10
rthritis  was  described  in  4%  to  79%8,10 of  these  patients,  and
ay be  divided  into  four  subtypes:  Charcots  joints,  septic
rthritis, acute  arthritis,  and  chronic  arthritis.10 Asymmetric
olyarthritis generally  involves  metacarpophalangeal  joints
nd proximal  and  distal  interphalangeal  joints,7 as  observed
h  and  without  musculoskeletal  manifestations.
Without  musculoskeletal
manifestations  (n  =  43)
p-value
1  (2)  1.000
0  1.000
0  1.000
0  1.000
5  (12)  0.071
1  (2)  1.000
0  0.140
0  1.000
ibody; anti-Ro, anti-Ro antibody; anti-La, anti-La antibody; aCL,
 G; LAC, lupus anticoagulant.
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n  the  present  ﬁve  pediatric  leprosy  patients.  Furthermore,
hronic polyarthritis  of  the  hands  mimicking  rheumatoid
rthritis was  also  reported  in  a  young  middle-aged  male  with
ype 1  leprosy  reaction.10
This  joint  involvement  is  generally  ignored  in  children
nd adolescents  with  leprosy,  and  chronic  polyarthritis  may
imic  pediatric  autoimmune  diseases,  especially  juvenile
diopathic arthritis,7,13 acute  leukemia,26 and  childhood
ystemic lupus  erythematosus.27 Of  note,  these  muscu-
oskeletal manifestations  were  rarely  reported  in  the  two
eprosy cases  that  involved  peripheral  and  hand  joints,13 and
lso in  one  case  associated  with  erythema  nodusum  that  was
reviously evidenced  by  this  group.14
Musculoskeletal  pain  syndromes  were  not  observed  in
his population  of  leprosy  patients  and  controls,  as  also
escribed in  the  present  healthy  and  obese  adolescents,
ith a  prevalence  ranging  from  0%  to  10%.20--22 Additionally,
o tendinitis  of  the  hand  associated  with  joint  involvement
as observed.
Interestingly, none  of  the  present  patients  had  joint
ypermobility, although  this  abnormality  has  been  reported
n up  to  20%  of  pediatric  population.20,21 This  alteration  is
ore frequent  in  schoolchildren,  with  reduced  prevalence  in
dolescents and  adults.  In  fact,  the  present  leprosy  patients
nd healthy  controls  were  mainly  adolescents,  which  may
ave contributed  to  the  absence  of  joint  hypermobility,  as
lso observed  in  another  study  by  the  authors.22
Autoantibodies  were  rarely  observed  in  the  present  pedi-
tric leprosy  patients.  IgM  anticardiolipin  was  the  most
requent autoantibodies  observed  in  leprosy  patients  with-
ut autoimmune  thrombosis  (13%),  as  also  observed  in
dult leprosy.  This  fact  differed  from  the  present  patients
ith childhood  systemic  lupus  erythematosus,  juvenile
ermatomyositis,28 and  RASopathies,29 which  presented  up
o 93%,  59%,  and  52%  of  a  variety  of  organ-speciﬁc  and  non
rgan-speciﬁc autoantibodies,  respectively.
Leprosy  is  a  chronic  granulomatous  infection  that  occurs
ainly with  cutaneous  and  neurological  manifestations,4,5
s  observed  in  the  present  patients  with  and  without  mus-
uloskeletal involvement.  This  disease  may  affect  daily
ife activities  and  health-related  quality  of  life  in  adult
atients,30 as  observed  herein.
Remarkably,  type  1  leprosy  reactions  with  nerve  func-
ion impairment  were  related  to  severe  disease,5 and  these
bnormalities were  also  associated  with  musculoskeletal
anifestations, indicating  a  simultaneous  involvement  of
erves and  joints  that  needed  immunosuppressant  and
ultibacillary treatment.  Moreover,  these  patients  could
resent permanent  joint  damage  with  swan  neck  deformi-
ies, mallet  ﬁnger,  and/or  ulnar  drift,10 which  requires  a
igorous and  prolonged  follow-up.
In  conclusion,  this  was  the  ﬁrst  study  to  identify  a
igh frequency  of  musculoskeletal  manifestations  associ-
ted with  nerve  dysfunction  in  pediatric  leprosy  patients.
ansen’s disease  should  be  included  in  the  differential  diag-
osis of  asymmetric  arthritis,  especially  in  endemic  regions.unding
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